Janssen Pharmaceuticals

Cidara and Janssen Pharmaceuticals (Janssen) have a worldwide license and collaboration agreement to develop and commercialize drug-Fc conjugates (DFCs) for the prevention and treatment of seasonal and pandemic influenza. Under the collaboration, Cidara will be responsible for the development and manufacturing of CD388 into the clinic and through Phase 2 clinical development, and Janssen will be responsible for late-stage development, manufacturing, registration and global commercialization.

Cidara has entered into a license agreement with Melinta Therapeutics under which Cidara has granted Melinta an exclusive license to commercialize rezafungin in the U.S. Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses. Melinta’s portfolio currently includes five commercial-stage antibiotics: BAXDELA® (delafloxacin), KIMYRSA™ (oritavancin), MINOCIN® (minocycline) for Injection, ORBACTIV® (oritavancin), and VABOMERE® (meropenem and vaborbactam) and a commercial-stage cardiovascular product, TOPROL-XL® (metoprolol succinate).

Cidara and Mundipharma have a strategic partnership to develop and commercialize rezafungin for the treatment and prevention of invasive fungal disease in all markets outside of the U.S. and Japan, which are retained by Cidara. Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East. Mundipharma is dedicated to bringing innovative treatments to patients in the areas of Pain & Supportive Care and Consumer Healthcare as well as other severe and debilitating disease areas.


Cidara welcomes inquiries regarding potential opportunities for collaboration across discovery, development and commercialization. For more details, please fill out the form below or email: